Abstract
The microtubule (MT) represents a highly validated target for therapy. Insights into the complex nature of the dynamic microtubule physiology will provide the basis for developing novel microtubule targeting agents with enhanced efficacy and minimised toxicity. In this article, with an emphasis on translational applications, we have summarised relevant aspects of tubulin physiology in the context of developing MT binding agents as therapeutic agents. Case studies were included to illustrate therapeutic developments in prostate cancer and current strategies to discover novel agents or targets for therapy.
Keywords: Microtubule (MT), microtubule associated proteins (MAPs), microtubule targeting agents (MTAs), chemotherapy, tubulin heterodimers, polymerases, angiogenesis, neutropenia, p21-activated kinase 6 (PAK6), prostate cancer
Current Pharmaceutical Design
Title:Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation
Volume: 18 Issue: 19
Author(s): Aswini Krishnan, James Wilson and Hing Y. Leung
Affiliation:
Keywords: Microtubule (MT), microtubule associated proteins (MAPs), microtubule targeting agents (MTAs), chemotherapy, tubulin heterodimers, polymerases, angiogenesis, neutropenia, p21-activated kinase 6 (PAK6), prostate cancer
Abstract: The microtubule (MT) represents a highly validated target for therapy. Insights into the complex nature of the dynamic microtubule physiology will provide the basis for developing novel microtubule targeting agents with enhanced efficacy and minimised toxicity. In this article, with an emphasis on translational applications, we have summarised relevant aspects of tubulin physiology in the context of developing MT binding agents as therapeutic agents. Case studies were included to illustrate therapeutic developments in prostate cancer and current strategies to discover novel agents or targets for therapy.
Export Options
About this article
Cite this article as:
Krishnan Aswini, Wilson James and Y. Leung Hing, Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation, Current Pharmaceutical Design 2012; 18 (19) . https://dx.doi.org/10.2174/138161212800626111
DOI https://dx.doi.org/10.2174/138161212800626111 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HPV-mediated Cervical Cancer: A Systematic Review on Immunological
Basis, Molecular Biology, and Immune Evasion Mechanisms
Current Drug Targets The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Current State of ERG as Biomarker in Prostatic Adenocarcinoma
Current Cancer Drug Targets Chemomodulating Effects of Flavonoids in Human Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Machine Learning and Perturbation Theory Machine Learning (PTML) in Medicinal Chemistry, Biotechnology, and Nanotechnology
Current Topics in Medicinal Chemistry Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier
Current Medicinal Chemistry Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Melatonin Induces Apoptosis and Inhibits the Proliferation of Cancer Cells via Reactive Oxygen Species-mediated MAPK and mTOR Pathways
Clinical Cancer Drugs Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma
Current Drug Targets Anti-tumor Effects of Curcuminoids in Glioblastoma Multiforme: An Updated Literature Review
Current Medicinal Chemistry Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology Anticancer Activity of Lectins from <i>Bauhinia purpurea</i> and <i>Wisteria floribunda</i> on Breast Cancer MCF-7 Cell Lines
Protein & Peptide Letters Synthesis of Aza-BODIPY Boron Difluoride PDT Agents to Promote Apoptosis in HeLa Cells
Letters in Organic Chemistry Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy
Current Drug Targets Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued)